Halozyme Therapeutics (HALO) Cash & Equivalents (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash & Equivalents data on file, last reported at $309.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $309.7 million, up 75.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $309.7 million (up 75.67% YoY), and the FY2025 annual result was $133.8 million, up 15.51% from the prior year.
• Cash & Equivalents grew to $309.7 million in Q1 2026 per HALO's latest filing, from $133.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $419.7 million in Q3 2025 and troughed at $61.9 million in Q2 2025.
• A 5-year average of $177.9 million and a median of $154.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 79.66% in 2022, then soared 171.95% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $234.2 million in 2022, then sank by 49.46% to $118.4 million in 2023, then slipped by 2.13% to $115.8 million in 2024, then increased by 15.51% to $133.8 million in 2025, then jumped by 131.47% to $309.7 million in 2026.
• Business Quant data shows HALO's Cash & Equivalents at $309.7 million in Q1 2026, $133.8 million in Q4 2025, and $419.7 million in Q3 2025.